Telix Pharmaceuticals (NASDAQ:TLX) Stock Keeps Outperform Rating at Wedbush

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating reissued by equities researchers at Wedbush in a note issued to investors on Wednesday, Benzinga reports. They currently have a $22.00 target price on the stock. Wedbush‘s target price points to a potential upside of 118.80% from the company’s previous close.

A number of other research analysts have also recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Friday, September 25th. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, September 21st. Finally, Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $20.50.

Telix Pharmaceuticals Price Performance

Shares of TLX traded down $1.11 during trading hours on Wednesday, reaching $10.06. 330,891 shares of the stock traded hands, compared to its average volume of 232,990. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16. Telix Pharmaceuticals has a 52-week low of $6.28 and a 52-week high of $13.11. The company’s 50-day moving average price is $11.49 and its two-hundred day moving average price is $10.78.

Institutional Trading of Telix Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. WoodTrust Financial Corp purchased a new stake in Telix Pharmaceuticals in the 3rd quarter worth $186,000. XY Capital Ltd lifted its stake in Telix Pharmaceuticals by 468.0% in the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after purchasing an additional 58,739 shares in the last quarter. Hennion & Walsh Asset Management Inc. purchased a new stake in Telix Pharmaceuticals in the 2nd quarter worth $1,731,000. Bank of America Corp DE raised its holdings in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares in the last quarter. Finally, Lazard Asset Management LLC raised its holdings in shares of Telix Pharmaceuticals by 15.7% during the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after acquiring an additional 39,400 shares in the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.

The company’s principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.